keyword
MENU ▼
Read by QxMD icon Read
search

Oligodendroglioma

keyword
https://www.readbyqxmd.com/read/28640702/diffuse-infiltrating-oligodendroglioma-and-astrocytoma
#1
Martin J van den Bent, Marion Smits, Johan M Kros, Susan M Chang
The new 2016 WHO brain tumor classification defines different diffuse gliomas primarily according to the presence or absence of IDH mutations ( IDH-mt) and combined 1p/19q loss. Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors. IDH-mt tumors have a more favorable prognosis, and tumors with low-grade histology especially tend evolve slowly. IDH-wt tumors are not a homogeneous entity and warrant further molecular testing because some have glioblastoma-like molecular features with poor clinical outcome...
June 22, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28603776/actionable-molecular-biomarkers-in-primary-brain-tumors
#2
Verena Staedtke, Omar Dildar A Dzaye, Matthias Holdhoff
Recent genome-wide studies of malignancies of the central nervous system (CNS) have revolutionized our understanding of the biology of these tumors. This newly gained knowledge provides a wealth of opportunity for biomarker driven clinical research. To date, however, only few of the available molecular markers truly influence clinical decision-making and treatment. The most widely validated markers in neuro-oncology presently are: 1) MGMT promoter methylation as a prognostic and predictive marker in glioblastoma, 2) co-deletion of 1p and 19q differentiating oligodendrogliomas from astrocytomas, 3) IDH1/2 mutations, and 4) select pathway-associated mutations...
July 2016: Trends in Cancer
https://www.readbyqxmd.com/read/28585606/extent-of-resection-and-timing-of-surgery-in-adult-low-grade-glioma
#3
Farhan A Mirza, Muhammad Shahzad Shamim
Low grade glioma is a group of WHO grade II tumours including diffuse astrocytoma, oligodendroglioma, and oligoastrocytoma. Strong evidence exists in literature now to support early surgery and higher extent of safe resection in improving outcomes. In this review, we are highlighting some of the important studies done in the last few years specifically addressing timing of surgery and extent of resection.
June 2017: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/28550465/differential-diagnosis-of-oligodendroglial-and-astrocytic-tumors-using-imaging-results-the-added-value-of-perfusion-mr-imaging
#4
Hyun Jung Yoon, Kook Jin Ahn, Song Lee, Jin Hee Jang, Hyun Seok Choi, So Lyung Jung, Bum Soo Kim, Shin Soo Jeun, Yong Kil Hong
PURPOSE: The purposes of the present study are to assess whether different characteristics of oligodendrogliomas and astrocytic tumors are visible on MR imaging and to determine the added value of perfusion imaging in conventional MR imaging when differentiating oligodendrogliomas from astrocytic tumors. METHODS: We retrospectively studied 22 oligodendroglioma and 54 astrocytic tumor patients, including glioblastoma multiforme (GBM). The morphological tumor characteristics were evaluated using MR imaging...
May 26, 2017: Neuroradiology
https://www.readbyqxmd.com/read/28550371/synchronous-gemistocytic-astrocytoma-idh-mutant-and-oligodendroglioma-idh-mutant-and-1p-19q-codeleted-in-a-patient-with-ccdc26-polymorphism
#5
Rachael A Vaubel, Thomas M Kollmeyer, Alissa A Caron, Emily G Barr Fritcher, Jesse S Voss, Haohai Liang, Robert B Jenkins, Caterina Giannini, Benjamin R Kipp
No abstract text is available yet for this article.
May 26, 2017: Acta Neuropathologica
https://www.readbyqxmd.com/read/28549927/molecular-classification-of-adult-diffuse-gliomas-conflicting-idh1-idh2-atrx-and-1p-19q-results
#6
Leomar Y Ballester, Jason T Huse, Guilin Tang, Gregory N Fuller
Until recently, the diagnosis of brain tumors was primarily based on microscopic examination of hematoxylin and eosin (H&E) stained tissue sections. The updated World Health Organization (WHO) classification of tumours of the central nervous system (CNS) incorporates genetic alterations into the classification system, with the goal of creating more homogenous disease categories with greater prognostic value. Hence, under the new classification system the diagnosis of diffuse gliomas incorporates the evaluation of mutations in the IDH1 and IDH2 genes and simultaneous deletion of chromosomes 1p and 19...
May 23, 2017: Human Pathology
https://www.readbyqxmd.com/read/28548216/pathology-of-oligodendroglia-an-overview
#7
Takashi Komori
Oligodendroglia are cells responsible for creating myelin sheaths for axons in the CNS. However, pathologies of oligodendroglia other than demyelination are not well understood due to the lack of adequate methods of characterizing pathological conditions affecting oligodendroglia in human tissue. This review discusses three major topics with the aim of clarifying some of the controversies in the study of oligodendroglia. The oligodendroglioma, a relatively indolent form of diffuse gliomas thought to originate in oligodendrocytes, has never demonstrated myelin formation on electron microscopy nor shown a constant expression of myelin-related proteins...
May 26, 2017: Neuropathology: Official Journal of the Japanese Society of Neuropathology
https://www.readbyqxmd.com/read/28547590/perfusion-and-diffusion-mri-signatures-in-histologic-and-genetic-subtypes-of-who-grade-ii-iii-diffuse-gliomas
#8
Kevin Leu, Garrett A Ott, Albert Lai, Phioanh L Nghiemphu, Whitney B Pope, William H Yong, Linda M Liau, Timothy F Cloughesy, Benjamin M Ellingson
The value of perfusion and diffusion-weighted MRI in differentiating histological subtypes according to the 2007 WHO glioma classification scheme (i.e. astrocytoma vs. oligodendroglioma) and genetic subtypes according to the 2016 WHO reclassification (e.g. 1p/19q co-deletion and IDH1 mutation status) in WHO grade II and III diffuse gliomas remains controversial. In the current study, we describe unique perfusion and diffusion MR signatures between histological and genetic glioma subtypes. Sixty-five patients with 2007 histological designations (astrocytomas and oligodendrogliomas), 1p/19q status (+ = intact/- = co-deleted), and IDH1 mutation status (MUT/WT) were included in this study...
May 25, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28535583/molecular-testing-of-brain-tumor
#9
REVIEW
Sung-Hye Park, Jaekyung Won, Seong-Ik Kim, Yujin Lee, Chul-Kee Park, Seung-Ki Kim, Seung-Hong Choi
The World Health Organization (WHO) classification of central nervous system (CNS) tumors was revised in 2016 with a basis on the integrated diagnosis of molecular genetics. We herein provide the guidelines for using molecular genetic tests in routine pathological practice for an accurate diagnosis and appropriate management. While astrocytomas and IDH-mutant (secondary) glioblastomas are characterized by the mutational status of IDH, TP53 , and ATRX , oligodendrogliomas have a 1p/19q codeletion and mutations in IDH, CIC , FUBP1 , and the promoter region of telomerase reverse transcriptase ( TERTp )...
May 2017: Journal of Pathology and Translational Medicine
https://www.readbyqxmd.com/read/28534152/cerebrospinal-fluid-dissemination-of-high-grade-gliomas-following-boron-neutron-capture-therapy-occurs-more-frequently-in-the-small-cell-subtype-of-idh1-r132h-mutation-negative-glioblastoma
#10
Natsuko Kondo, Rolf F Barth, Shin-Ichi Miyatake, Shinji Kawabata, Minoru Suzuki, Koji Ono, Norman L Lehman
We have used boron neutron capture therapy (BNCT) to treat patients in Japan with newly diagnosed or recurrent high-grade gliomas and have observed a significant increase in median survival time following BNCT. Although cerebrospinal fluid dissemination (CSFD) is not usually seen with the current standard therapy of patients with glioblastoma (GBM), here we report that subarachnoid or intraventricular CSFD was the most frequent cause of death for a cohort of our patients with high-grade gliomas who had been treated with BNCT...
May 22, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28527519/-adult-intramedullary-gliomas
#11
C Campello, F Parker, S Slimani, A Le Floch, A Herbrecht, N Aghakhani, C Lacroix, H Loiseau, J P Lejeune, G Perrin, J Honnorat, H Dufour, O Chinot, D Figarella, L Bauchet, H Duffau, M Lonjon, P Labauge, M Messerer, J P Daures, P Fabbro, B Ducot
OBJECTIVES: Intramedullary gliomas are rare tumors accounting for less than 4% of all primary central nervous system tumors. The aims of this retrospective multicenter study were to assess their natural outcome as well as management. METHODS AND MATERIALS: We studied 332 patients from 1984 to 2011. Histopathological examination revealed 72% ependymomas (94% were low grade tumors), 24% astrocytomas (29% were high grade tumors), 2.4% mixed gliomas and 1.7% oligodendrogliomas...
May 17, 2017: Neuro-Chirurgie
https://www.readbyqxmd.com/read/28522666/discrimination-between-glioma-grades-ii-and-iii-using-dynamic-susceptibility-perfusion-mri-a-meta-analysis
#12
Anna F Delgado, Alberto F Delgado
BACKGROUND: DSC perfusion has been evaluated in the discrimination between low-grade and high-grade glioma but the diagnostic potential to discriminate beween glioma grades II and III remains unclear. PURPOSE: Our aim was to evaluate the diagnostic accuracy of relative maximal CBV from DSC perfusion MR imaging to discriminate glioma grades II and III. DATA SOURCES: A systematic literature search was performed in PubMed/MEDLINE, Embase, Web of Science, and ClinicalTrials...
May 18, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28516268/gpna-inhibits-the-sodium-independent-transport-system-l-for-neutral-amino-acids
#13
Martina Chiu, Cosimo Sabino, Giuseppe Taurino, Massimiliano G Bianchi, Roberta Andreoli, Nicola Giuliani, Ovidio Bussolati
L-γ-Glutamyl-p-nitroanilide (GPNA) is widely used to inhibit the glutamine transporter ASCT2, although it is known that it also inhibits other sodium-dependent amino acid transporters. In a panel of human cancer cell lines, which express the system L transporters LAT1 and LAT2, GPNA inhibits the sodium-independent influx of leucine and glutamine. The kinetics of the effect suggests that GPNA is a low affinity, competitive inhibitor of system L transporters. In Hs683 human oligodendroglioma cells, the incubation in the presence of GPNA, but not ASCT2 silencing, lowers the cell content of leucine...
May 17, 2017: Amino Acids
https://www.readbyqxmd.com/read/28512409/immunoglobulin-d-multiple-myeloma-presenting-as-spontaneous-fracture
#14
Samer Al Hadidi, Khalil Katato, Ghassan Bachuwa
Immunoglobulin D multiple myeloma is a rare type of multiple myeloma that usually presents as bone pain, fatigue, or weight loss. We report a case of immunoglobulin D multiple myeloma in a 53-year-old Caucasian male patient with previous medical history of anaplastic oligodendroglioma status post-surgical resection who was evaluated for back pain while mowing the lawn. His physical examination showed tenderness over the lower thoracic vertebrae with no sensory or motor impairment. Initial lab investigations showed normocytic anemia and hypercalcemia with low parathyroid hormone...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28498059/oligodendroglioma-resection-a-surveillance-epidemiology-and-end-results-seer-analysis
#15
Ali A Alattar, Michael G Brandel, Brian R Hirshman, Xuezhi Dong, Kate T Carroll, Mir Amaan Ali, Bob S Carter, Clark C Chen
OBJECTIVE The available evidence suggests that the clinical benefits of extended resection are limited for chemosensitive tumors, such as primary CNS lymphoma. Oligodendroglioma is generally believed to be more sensitive to chemotherapy than astrocytoma of comparable grades. In this study the authors compare the survival benefit of gross-total resection (GTR) in patients with oligodendroglioma relative to patients with astrocytoma. METHODS Using the Surveillance, Epidemiology, and End Results (SEER) Program (1999-2010) database, the authors identified 2378 patients with WHO Grade II oligodendroglioma (O2 group) and 1028 patients with WHO Grade III oligodendroglioma (O3 group)...
May 12, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28497806/management-of-diffuse-low-grade-gliomas-in-adults-use-of-molecular-diagnostics
#16
REVIEW
Jan Buckner, Caterina Giannini, Jeanette Eckel-Passow, Daniel Lachance, Ian Parney, Nadia Laack, Robert Jenkins
Diffuse WHO grade II gliomas are histologically and genetically heterogeneous. The 2016 WHO classification redefines grade II gliomas with respect to morphological and molecular tumour alterations: grade II oligodendrogliomas are defined by the presence of whole-arm codeletion in chromosomal arms 1p/19q, whereas isocitrate dehydrogenase (IDH) mutations define subclasses of astrocytoma. Although histological grade remains useful, the prognoses of patients with glioma are more tightly associated with molecular alterations than with grade, and chromosomal and gene array technologies are becoming increasingly beneficial in understanding tumour genetic heterogeneity...
June 2017: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/28496364/oligodendrogliomas-in-pediatric-and-adult-patients-an-outcome-based-study-from-the-surveillance-epidemiology-and-end-result-database
#17
Christine Sm Lau, Krishnaraj Mahendraraj, Ronald S Chamberlain
INTRODUCTION: Oligodendrogliomas (OGs) account for <20% of all intracranial tumors and 25% of gliomas. Despite improvements in imaging techniques allowing for earlier diagnosis, OG is rare among the pediatric population. This study examines a large cohort of OG patients in an effort to define the demographic, clinical, and pathologic factors associated with clinical and survival outcomes. METHODS: Data on 7,001 OG patients were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (1973-2013)...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28492209/some-characteristics-of-gliomas-managed-at-a-neurosurgery-centre-in-nigeria
#18
Chika A Ndubuisi, Samuel C Ohaegbulam, Mark O Chikani, Wilfred C Mezue, Tobechi Mbadugha, Mark Okhueleigbe
BACKGROUND: Gliomas are important primary brain tumours with varying prognosis. AIM: To study the histology characteristics of brain gliomas managed in a Neurosurgical centre in Nigeria. MATERIALS AND METHODS: A retrospective analysis of prospectively recorded data of patients managed for intracranial gliomas at our Hospital for Neurosurgery, between year 2006 and 2015. Only the patients with conclusive histology diagnosis following surgery were analysed...
January 2017: Nigerian Postgraduate Medical Journal
https://www.readbyqxmd.com/read/28490687/-association-between-glioblastoma-with-oligodendroglioma-component-and-subcortical-hemorrhage-a-case-report
#19
Hidenori Hoda, Atsushi Shimizu, Keita Shibahashi, Kazuo Hanakawa, Takafumi Ide
No abstract text is available yet for this article.
May 2017: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/28488951/treatment-outcomes-in-1p19q-co-deleted-partially-deleted-gliomas
#20
Mairéad G McNamara, Haiyan Jiang, Mary Jane Lim-Fat, Solmaz Sahebjam, Tim-Rasmus Kiehl, Jason Karamchandani, Claire Coire, Caroline Chung, Barbara-Ann Millar, Normand Laperriere, Warren P Mason
BACKGROUND: Radiotherapy with procarbazine, lomustine, and vincristine improves overall survival (OS) in patients with 1p19q co-deleted anaplastic oligodendroglioma/anaplastic oligoastrocytoma. METHODS: This retrospective analysis investigated outcomes in patients with 1p19q co-deleted/partially deleted oligodendroglioma, oligoastrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma. OS and progression-free survival (PFS) were analyzed using the Kaplan-Meier method and prognostic factors using the Cox proportional hazard model...
May 2017: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
keyword
keyword
15140
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"